diff --git a/domains/health/federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level.md b/domains/health/federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level.md index a94976ce0..003bd33d5 100644 --- a/domains/health/federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level.md +++ b/domains/health/federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level.md @@ -10,7 +10,7 @@ agent: vida sourced_from: health/2026-04-22-kff-medicare-glp1-bridge-lis-exclusion.md scope: structural sourcer: KFF Health Policy -related: ["generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost"] +related: ["generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level", "medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access", "medicare-glp1-bridge-program"] --- # Federal GLP-1 expansion programs reproduce the access hierarchy at the program design level, not just through market dynamics @@ -23,3 +23,10 @@ The Medicare GLP-1 Bridge program demonstrates that the GLP-1 access inversion o **Source:** KFF 2025 poll demographic breakdown Age 65+ adults show only 9% GLP-1 usage compared to 22% for ages 50-64, directly reflecting Medicare's statutory exclusion of weight-loss drugs. This creates a sharp discontinuity at the Medicare eligibility threshold despite this population having the highest obesity burden and worst health outcomes. The demographic pattern confirms that structural coverage exclusions, not clinical need, determine access. + + +## Supporting Evidence + +**Source:** National Law Review, FDA April 1 2026 clarification + +Despite FDA's February 2026 announcement of 'decisive enforcement action' against non-approved compounded GLP-1s, compounded semaglutide remains available via 503A pharmacies at $99/month as of April 2026. However, the 4 prescription/month safe harbor limit means this pathway is structurally unavailable at population scale (estimated 100K+ patients cannot be served through 503A). State regulatory responses have created a patchwork: some states enacted protective legislation for patient access while others imposed stricter controls. The access hierarchy persists with the affordable channel legally precarious and architecturally constrained. diff --git a/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md b/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md index 09c2f9026..3f303b1f3 100644 --- a/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md +++ b/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md @@ -95,3 +95,10 @@ Coverage withdrawal is concentrated among regional health systems (Allina, RWJBa **Source:** Atlanta Fed / FRBSF, March 2026 The AI productivity concentration pattern mirrors the GLP-1 access inversion: AI gains concentrate in high-skill, high-education populations (0.8% vs 0.4%) who are least burdened by chronic disease, while chronic disease concentrates in low-skill populations who see minimal AI productivity benefit. This creates a double inversion where both therapeutic access (GLP-1) and economic productivity gains (AI) flow away from populations with highest disease burden, compounding health-wealth divergence. + + +## Extending Evidence + +**Source:** National Law Review, FDA April 1 2026 clarification on compounded GLP-1 policy + +FDA April 1, 2026 clarification establishes that 503A pharmacies retain a narrow safe harbor (4 or fewer prescriptions per month) for compounded semaglutide at $99/month, but this limit is architecturally designed to prevent population-scale access. The 503B outsourcing facility pathway is effectively closed (neither semaglutide nor tirzepatide appear on FDA's 503B bulks list or drug shortage list). Federal courts have blocked some 503B enforcement through injunctions, creating a legally contested patchwork. The compounding channel survived two grace period deadlines (April/May 2025) and remains operational in April 2026, but FDA enforcement is systematically closing it through regulatory mechanics rather than outright prohibition. This makes 2031-2033 patent expiry the next realistic systemic access event for population-scale affordable GLP-1 access in the US. diff --git a/domains/health/glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap.md b/domains/health/glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap.md index 91af34c27..fd49d249f 100644 --- a/domains/health/glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap.md +++ b/domains/health/glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap.md @@ -32,3 +32,10 @@ Covered lives declined from 3.6M to 2.8M (22% drop) while utilization among thos **Source:** PHTI December 2025 + Mercer 2026 Scope resolution: the 3.6M → 2.8M covered lives decline (22% reduction) applies to different populations than the 34% behavioral mandate increase. Population experiencing coverage loss: health system-employed populations (Allina, RWJBarnabas, Ascension), state government employees (4 states withdrawing), Kaiser California Medicaid/commercial eliminations, regional and small-group insurers restricting small employer plans. Mass General Brigham Health Plan example: small employers (under 50 subscribers) no longer offered GLP-1 obesity coverage as of January 1, 2026; employers with 50+ subscribers offered as add-on option. This is employer size bifurcation, not a contradiction — large sophisticated employers keep coverage with conditions while small group plans eliminate coverage entirely. + + +## Extending Evidence + +**Source:** National Law Review, FDA April 1 2026 clarification + +The FDA's April 2026 clarification targeted combination formulations (semaglutide + vitamin B12) that compounders used to escape the 'essentially a copy' standard, signaling regulatory skepticism. The 503A safe harbor requires individualized clinical justification from prescribers demonstrating 'significant difference' for each patient, with boilerplate clinical rationale deemed insufficient. This creates additional administrative burden that further constrains the compounding access pathway even within the 4 Rx/month limit. diff --git a/inbox/queue/2026-04-01-natlawreview-fda-glp1-compounding-april-clarification.md b/inbox/archive/health/2026-04-01-natlawreview-fda-glp1-compounding-april-clarification.md similarity index 98% rename from inbox/queue/2026-04-01-natlawreview-fda-glp1-compounding-april-clarification.md rename to inbox/archive/health/2026-04-01-natlawreview-fda-glp1-compounding-april-clarification.md index 3d6cda00b..6f7bb949a 100644 --- a/inbox/queue/2026-04-01-natlawreview-fda-glp1-compounding-april-clarification.md +++ b/inbox/archive/health/2026-04-01-natlawreview-fda-glp1-compounding-april-clarification.md @@ -7,9 +7,12 @@ date: 2026-04-01 domain: health secondary_domains: [] format: legal-analysis -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-04-30 priority: high tags: [glp-1, compounding-pharmacy, FDA, enforcement, semaglutide, access, regulatory, 503A, 503B] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content